Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Simcere Pharmaceutical Group Limited
先聲藥業集團有限公司
(Incorporated in Hong Kong with limited liability)
(Stock code: 2096)

VOLUNTARY ANNOUNCEMENT

INCLUSION OF SANBEXIN® SUBLINGUAL TABLETS INTO THE NEW NATIONAL REIMBURSEMENT DRUG LIST

This announcement is made by Simcere Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform shareholders and potential investors of the Company regarding the latest business development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on 14 November 2026, Sanbexin® sublingual tablets (edaravone and dexborneol sublingual tablets) were officially included in the "Drugs Catalogue for the National Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance (2026)" (《國家基本醫療保險、工傷保險和生育保險藥品目錄(2026年)》) issued by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security, with effect from January 1, 2027. In addition, Sanbexin® injection has successfully completed the third renewal under the National Reimbursement Drug List ("**NRDL**").

With both Sanbexin® injection and Sanbexin® sublingual tablets included in the NRDL, medical insurance coverage for the full 14-day course of treatment for acute ischemic stroke ("**AIS**") is expected to be achieved, which will enable more stroke patients to benefit from the innovative brain cytoprotective treatment regimen and reduce the medication burden on patients.

ABOUT SANBEXIN® SUBLINGUAL TABLETS

Sanbexin® sublingual tablets are a brain cytoprotective agent composed of edaravone and dexborneol, with antioxidant, anti-inflammatory and synergistic effects, which can significantly reduce brain cell damage caused by AIS. The unique sublingual formulation disintegrates rapidly upon contact with saliva under the tongue, and is quickly absorbed into the bloodstream through the sublingual venous plexus to exert its therapeutic effect, providing greater flexibility in the treatment of stroke. Sanbexin® sublingual tablets can be used together with Sanbexin® injection as a sequential therapy, enabling patients to receive a complete course of treatment both in hospital and after discharge.

Sanbexin® sublingual tablets were approved for marketing in China in December 2024 for improving neurological symptoms, activities of daily living and functional impairments caused by AIS. In August 2024, Sanbexin® sublingual tablets were granted the Breakthrough Therapy designation by the United States Food and Drug Administration (FDA), becoming the first innovative drug in the world in the field of stroke treatment to receive such designation, and the first innovative drug in the field of neuroscience in China to receive such designation.

ABOUT THE GROUP

The Company is an innovation and R&D-driven pharmaceutical company and the Group has established a "State Key Laboratory of Neurology and Oncology Drug Development". The Group focuses on the therapeutic areas of neuroscience, anti-oncology, autoimmune and anti-infection, with forward-looking layout of disease areas that may have significant clinical needs in the future, aiming to achieve the mission of "for patients, for life". Driven by its in-house R&D efforts and synergistic innovation, the Company has established strategic cooperation partnerships with many innovative companies and research institutes.

By order of the Board
Simcere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer

Hong Kong, November 16, 2026

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director; Mr. WAN Yushan and Ms. WANG Xi as the executive Directors; Mr. TANG Renhong as the non-executive Director; Mr. SONG Ruilin, Mr. WANG Jianguo, Mr. WANG Xinhua and Mr. SUNG Ka Woon as the independent non-executive Directors.